首页> 外文期刊>The Egyptian Journal of Radiology and Nuclear Medicine >Diffusion-weighted MRI in liver fibrosis staging: Added value of normalized ADC using spleen and renal cortex as reference organs
【24h】

Diffusion-weighted MRI in liver fibrosis staging: Added value of normalized ADC using spleen and renal cortex as reference organs

机译:肝纤维化分期的弥散加权MRI:以脾脏和肾皮质为参考器官的归一化ADC的附加值

获取原文
       

摘要

Aim To evaluate the potential value of the spleen and renal cortex as a reference organ to improve the performance of DWI in the assessment of liver fibrosis. Material and methods 44 subjects were included: 30 patients with chronic viral hepatitis and 14 age matched volunteers. They were subjected to diffusion weighted MRI (DWI). Liver ADC, normalized ADC (ratio between ADC of liver to spleen (S-ADC) and renal cortex (R-ADC)) was calculated. Data was analyzed and ROC was used to evaluate the performance of ADC, S-ADC and R-ADC. Results No significant difference between spleen ADC and renal ADC values between patient group and control group or in-betweens different fibrosis stages. The mean liver ADC was significantly lower in cirrhotic patients than control group (1.59 ± 0.024 versus 1.55 ± 0.036 × 10 ?3 mm 2 /s, P = 0.009) with some overlap in different fibrosis grades. With exception to stage 1 fibrosis, the mean S-ADC value was significantly lower in patients with different hepatic fibrosis stages in comparison to control group (P 0.02–0.001). Significant negative correlation was noted between S-ADC value and fibrosis stage (r = ?0.75, p 0.001). It had significant difference between stage 0 compared to stage 2, 3, and 4 as well as between stage 4 in comparison to stage 1, 2 and 3. S-ADC had a significant ability to differentiate between stages 0–1 Vs stage 2–4, stage 0–2 Vs stage 3–4 as well as stage 0–3 Vs stage 4. Significant negative correlation was noted between R-ADC value and fibrosis stage (r = ?0.68, p 0.001). The mean R-ADC value was lower in patients with liver fibrosis compared to volunteers with significant difference between stage 0 and 3 and between stage 0 and 4 (P 0.001). It had significant difference between stage 0 compared to stage 3, and 4 as well as in stage 4 in comparison to stage 1 and 2. R-ADC has a significant ability to differentiate between stages 0–1 Vs stage 2–4, stage 0–2 Vs stage 3–4 as well as stage 0–3 Vs stage 4. ROC analysis showed higher performance using S-ADC in comparison to liver ADC and R-ADC while R-ADC had higher performance in comparison to liver ADC. The AUC, sensitivity, specificity, PPV, NPV and k-value for detection of fibrotic stages ?2 (0.85, 95.8%, 60%, 74%, 92% and 0.85 for S-ADC Vs 0.68, 66.7%, 60%, 66%, 60% and 0.28 for ADC and 0.85, 95.8%, 50%, 69%, 91% and 0.47 for R-ADC). and in detection of fibrotic stages ?3 was (0.86, 100%, 52%, 61%, 100% and 0.48 for S-ADC Vs 0.63, 63%, 52%, 50%, 65% and 0.14 for ADC and 0.88, 100%, 44%, 57%, 100% and 0.40 for R-ADC) while for fibrosis stage 4, the corresponding values was (1, 100%, 100%, 100%, 100% and 1 for S-ADC Vs 0.7, 81%, 54%, 37%, 90% and 0.26 for ADC and 0.65, 100%, 65%, 45%, 100% and 0.43 for R-ADC) respectively. Conclusion Normalized liver ADC using the spleen and kidney increases the performance of ADC in the evaluation of liver fibrosis which is highest in spleen normalized ADC.
机译:目的评估脾脏和肾皮质作为参考器官的潜在价值,以改善DWI在评估肝纤维化中的表现。材料和方法纳入44名受试者:30例慢性病毒性肝炎患者和14名年龄匹配的志愿者。他们接受了弥散加权MRI(DWI)。计算肝脏ADC,归一化ADC(肝脾ADC(S-ADC)与肾皮质(R-ADC)之比)。分析数据,并使用ROC评估ADC,S-ADC和R-ADC的性能。结果患者组与对照组之间或不同纤维化阶段之间的脾脏ADC和肾ADC值之间无显着差异。肝硬化患者的平均肝ADC值显着低于对照组(1.59±0.024对1.55±0.036×10?3 mm 2 / s,P = 0.009),并且在不同纤维化级别上存在一定的重叠。除了1期纤维化,与对照组相比,不同肝纤维化阶段的患者的S-ADC平均值均显着降低(P 0.02– <0.001)。 S-ADC值与纤维化分期之间存在显着的负相关性(r =≤0.75,p <0.001)。与阶段2、3和4相比,阶段0之间有显着差异,与阶段1、2和3相比,阶段4之间具有显着差异。S-ADC具有区分阶段0–1和阶段2–3的显着能力。在图4中,阶段0-2 Vs到阶段3-4以及阶段0-3 Vs到阶段4。R-ADC值与纤维化阶段之间存在显着的负相关性(r =?0.68,p <0.001)。与志愿者相比,肝纤维化患者的平均R-ADC值要低,在0和3期之间以及0和4期之间存在显着差异(P <0.001)。与第3阶段相比,第0阶段与第4阶段之间有显着差异;与第1阶段和第2阶段相比,第4阶段具有显着差异。R-ADC具有区分0–1阶段与2–4阶段,0阶段的显着能力。 –2 Vs的3–4阶段以及0–3 Vs的阶段4。ROC分析显示,与肝ADC和R-ADC相比,使用S-ADC具有更高的性能,而R-ADC与肝ADC相比具有更高的性能。用于检测纤维化阶段?2的AUC,灵敏度,特异性,PPV,NPV和k值(S-ADC Vs为0.68、66.7%,60%的0.85、95.8%,60%,74%,92%和0.85,对于ADC为66%,60%和0.28,对于R-ADC为0.85、95.8%,50%,69%,91%和0.47)。在纤维化分期的检测中,对于S-ADC Vs,Δ3为(0.86、100%,52%,61%,100%和0.48,对于ADC为0.63、63%,52%,50%,65%和0.14,对于0.88,对于R-ADC,分别为100%,44%,57%,100%和0.40),而对于纤维化第4期,相应的值为(对于S-ADC Vs为0.7,分别为1,100%,100%,100%,100%和1 ,对于ADC分别为81%,54%,37%,90%和0.26,对于R-ADC分别为0.65、100%,65%,45%,100%和0.43)。结论使用脾肾标准化肝ADC可以提高ADC评估肝纤维化的性能,这在脾标准化ADC中是最高的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号